Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
AssigneeBrainbox Solutions, Inc.
InventorTimothy E. Van Meter
Life of this patent
Estimating the term…
Abstract
Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of neurological injury or disease or brain injury, such as traumatic brain injury (TBI), are provided in which certain newly discovered protein biomarkers are detected in a biological sample of a subject undergoing testing or evaluation. The methods allow for detection of changes in levels, amounts, or concentrations of the protein biomarkers in a subject compared with those of controls. Detection of the protein biomarkers, and/or levels thereof, provides an indication of biological and biochemical events, e.g., at a cellular level, that are occurring in the subject who is undergoing testing or analysis for the neurological injury or brain injury.
Claims10
A method of assessing whether a therapy or treatment regimen for a neurological injury or brain injury is effective in a subject, the method comprising:
- (A) quantitatively measuring the levels of the one or more protein biomarkers, or fragments thereof, in a biological sample obtained from a subject at a first time point prior to initiation of a therapy or treatment regimen for a neurological or brain injury, wherein the one or more protein biomarkers or fragments thereof comprise Astrotactin 2 (ASTN2);
- (B) quantitatively measuring the levels of the same, one or more protein biomarkers, or fragments thereof, in step (A), in a biological sample obtained from the subject at a second time point, after initiation of the therapy or treatment regimen;
- and
- (C) (i) ceasing treatment for neurological injury or brain injury when the measured levels of the one or more protein biomarkers, or fragments thereof, are decreased or trending to normal levels, in the biological sample obtained at the second time point, as compared with measured levels of the one or more protein biomarkers, or fragments thereof, at the first time point;
- or
- (ii) continuing treatment for neurological injury or brain injury when the measured levels of the one or more protein biomarkers, or fragments thereof, are increased or trending to abnormal levels, in the biological sample obtained at the second time point, as compared with measured levels of the one or more protein biomarkers, or fragments thereof, at the first time point.
A method of detecting one or more protein biomarkers or fragments thereof, in a biofluid sample obtained from a subject having, or suspected of having a neurological injury or brain injury, the method comprising the steps of:
- A) obtaining the biofluid sample from the patient;
- and
- B) detecting Astrotactin 2 (ASTN2) in the biofluid sample by an assay or mass spectrometry.
Dependencies are inferred from the claim text.